Mar 31, 2026 by Jeremy BowmanOracle's Layoffs Raise a Hard Question: Is the AI Pivot Worth the Human Cost?Oracle cut 30,000 jobs this morning.
Mar 31, 2026 by Keith NoonanGameStop Revenue Is Down. Should Investors Consider Buying the Famous Meme Stock on the Dip?GameStop's revenue fell double digits in Q4, but that's not the most important story surrounding the stock.
Mar 31, 2026 by James BrumleyPrediction: This Will Be Alphabet's Stock Price in 5 YearsCurrent challenges or not, the company's long-term future seems pretty compelling.
Mar 31, 2026 by Keith NoonanGameStop Revenue Is Down. Should Investors Consider Buying the Famous Meme Stock on the Dip?GameStop's revenue fell double digits in Q4, but that's not the most important story surrounding the stock.
Mar 31, 2026 by James BrumleyPrediction: This Will Be Alphabet's Stock Price in 5 YearsCurrent challenges or not, the company's long-term future seems pretty compelling.
Mar 31, 2026 by Alex CarchidiUp 17% in 1 Day, Is the Bittensor (TAO) Cryptocurrency a Buy Right Now?This coin is ambitious, and it's going to be taking a lot of risks.
Mar 31, 2026 by Jeremy BowmanOracle's Layoffs Raise a Hard Question: Is the AI Pivot Worth the Human Cost?Oracle cut 30,000 jobs this morning.
Mar 31, 2026 by Lee SamahaHere's Why Shares in Hecla Mining Surged Higher TodaySilver prices and silver stocks soared today, and that's good news for a company that's all-in on silver in 2026.
Mar 31, 2026 by Marc GubertiWhy Savvy Investors Are Loading Up on These 2 Stocks Amid Market ChaosBuying dips on promising growth stocks has been a winning formula for navigating short-term market chaos.
Mar 31, 2026 by David Jagielski, CPAHere's How Investing in the Stock Market Can Help You Retire EarlyInvesting in exchange-traded funds (ETFs) can be a great way to minimize risk while also putting you in an excellent position to grow your portfolio over the long term.
Mar 31, 2026 by Prosper Junior BakinyThe Dividend King That's Raised Its Payout for 63 Consecutive YearsThis healthcare leader can weather almost any storm.
Mar 31, 2026 by Dave KovaleskiWant $1 Million in Retirement? This 1 AI Stock Has the Growth Rate to Get You There From $10,000.This stock has had an incredible past decade. Will the next decade be as good?
Mar 31, 2026 by Chris NeigerWhy Aehr Test Systems Stock Jumped TodayShareholders are optimistic about the company's latest announcement.
Mar 31, 2026 by Leo SunThe Great Repricing Crushed This Cybersecurity Growth Stock. That's a Buying Opportunity.Zscaler looks undervalued after its latest pullback.
Mar 31, 2026 by Rich SmithWhy Alphabet Stock Popped TodayAlphabet just kicked a rival while it's down.
Mar 31, 2026 by Lee SamahaHere's Why Shares in SSR Mining Popped Higher TodayA higher gold price and some positive recent corporate developments drove the stock today,
Mar 31, 2026 by Matt DiLallo3 Dividend Stocks Paying Over 6.6% That Are Worth a Closer LookThese REITs offer enticing yields.
Mar 31, 2026 by James Halley3 Reasons to Buy NewLake Capital Partners Stock and 1 Reason Not ToThe cannabis REIT has fallen more than 6% so far this year. Is it time to buy the stock?
Mar 31, 2026 by James BrumleyThis Magnificent Software Stock Is Down 35%. Buy It Before It Sets a New All-Time High.Investors made an understandable knee-jerk decision that then took on a life of its own. But this company's bigger-picture bullish thesis is still perfectly intact.
Mar 31, 2026 by Lawrence NgaDown 80%, Is Duolingo Stock a Buy Now?As the company resets its strategy, investors need to look beyond the share price and focus on what truly matters.
Mar 31, 2026 by Leo SunBetter Dividend Stock: Realty Income vs. AGNCWhich of these dividend stocks has a brighter future?
Mar 31, 2026 by Brett SchaferIndividual Investors Could Get a Rare Shot at Buying Into SpaceX From Day OneThe gigantic private company may allocate up to 30% of IPO shares to retail investors, potentially raising tens of billions of dollars from individuals.
Mar 31, 2026 by James BrumleyWhy Agios Pharmaceuticals Stock Is Up More Than 21% TodayThe young drugmaker's sickle cell treatment is receiving special consideration from the United States' top drug regulator.
